blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1423363

EP1423363 - ORAL ANTIDIABETIC AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.02.2007
Database last updated on 02.11.2024
Most recent event   Tooltip12.12.2008Lapse of the patent in a contracting state
New state(s): CY		published on 14.01.2009  [2009/03]
Applicant(s)For all designated states
Warner-Lambert Company LLC
235 East 42nd Street
New York, NY 10017 / US
[2007/11]
Former [2006/16]For all designated states
Warner-Lambert Company LLC
201 Tabor Road Morris Plains
New Jersey 07950 / US
Former [2004/23]For all designated states
Warner-Lambert Company LLC
201 Tabor Road
Morris Plains, New Jersey 07950 / US
Inventor(s)01 / BIGGE, Christopher F., Pfizer Global Res. & Dev.
Ann Arbor Lab., 2800 Plymouth Rd
Ann Arbor, MI4810 5 / US
02 / BRIDGES, Alexander J., Pfizer Global Res. & Dev.
Ann Arbor Laboratories, 2800 Plymouth Road
Ann Arbor, MI 48105 / US
03 / CASIMIRO-GARCIA, A., Pfizer Global Res.& Dev.
Ann Arbor Laboratories, 2800 Plymouth Road
Ann Arbor, r, MI 48105 / US
04 / FAKHOURY, Stephen A. Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
Ann Arbor, MI 48105 / US
05 / LEE, Helen T. Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
Ann Arbor, MI 48105 / US
06 / REED, Jessica E. Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
Ann Arbor, MI 48105 / US
07 / SCHAUM, Robert P. Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
Ann Arbor, MI 48105 / US
08 / SCHLOSSER, Kevin M. Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
Ann Arbor, MI 48105 / US
09 / SEXTON, Karen E. Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
Ann Arbor, MI 48105 / US
10 / ZHOU, Hairong Pfizer Global Res. & Dev.
Ann Arbor Laboratories 2800 Plymouth Road
AnnArbor, MI 4810 5 / US
 [2004/23]
Representative(s)Rutt, Jason Edward
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [2004/23]Rutt, Jason Edward
Pfizer Limited European Patents Department Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date02745739.915.07.2002
[2004/23]
WO2002IB02843
Priority number, dateUS20010315728P29.08.2001         Original published format: US 315728 P
[2004/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO03018553
Date:06.03.2003
Language:EN
[2003/10]
Type: A1 Application with search report 
No.:EP1423363
Date:02.06.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 06.03.2003 takes the place of the publication of the European patent application.
[2004/23]
Type: B1 Patent specification 
No.:EP1423363
Date:19.04.2006
Language:EN
[2006/16]
Search report(s)International search report - published on:EP06.03.2003
ClassificationIPC:C07D207/32, C07D263/32, C07D413/12, C07D403/12, C07D401/12
[2004/23]
CPC:
C07D207/325 (EP); C07D413/12 (EP,KR); A61P3/00 (EP);
A61P3/04 (EP); A61P3/06 (EP); A61P3/08 (EP);
A61P3/10 (EP); A61P7/02 (EP); A61P9/10 (EP);
C07D207/327 (EP); C07D207/34 (EP); C07D209/08 (EP);
C07D263/32 (EP); C07D263/58 (EP); C07D277/26 (EP);
C07D309/38 (EP); C07D401/10 (EP); C07D401/12 (EP);
C07D403/12 (EP); C07D413/10 (EP); C07D413/14 (EP);
C07D417/12 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2004/23]
Extension statesAL20.02.2004
LT20.02.2004
LV20.02.2004
MK20.02.2004
RO20.02.2004
SI20.02.2004
TitleGerman:ORALE ANTIDIABETISCHE WIRKSTOFFE[2004/23]
English:ORAL ANTIDIABETIC AGENTS[2004/23]
French:AGENTS ANTIDIABETIQUES ORAUX[2004/23]
Entry into regional phase20.02.2004National basic fee paid 
20.02.2004Designation fee(s) paid 
20.02.2004Examination fee paid 
Examination procedure19.08.2002Request for preliminary examination filed
International Preliminary Examining Authority: EP
20.02.2004Amendment by applicant (claims and/or description)
20.02.2004Examination requested  [2004/23]
06.08.2004Despatch of a communication from the examining division (Time limit: M04)
04.11.2004Reply to a communication from the examining division
18.01.2005Despatch of a communication from the examining division (Time limit: M04)
05.05.2005Reply to a communication from the examining division
04.10.2005Communication of intention to grant the patent
14.02.2006Fee for grant paid
14.02.2006Fee for publishing/printing paid
Divisional application(s)EP05104581.3  / EP1577305
Opposition(s)22.01.2007No opposition filed within time limit [2007/13]
Fees paidRenewal fee
19.07.2004Renewal fee patent year 03
01.08.2005Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT19.04.2006
BE19.04.2006
CH19.04.2006
CY19.04.2006
CZ19.04.2006
EE19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
TR19.04.2006
LU15.07.2006
BG19.07.2006
DK19.07.2006
SE19.07.2006
GR20.07.2006
MC31.07.2006
PT19.09.2006
[2009/03]
Former [2008/37]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
EE19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
TR19.04.2006
LU15.07.2006
BG19.07.2006
DK19.07.2006
SE19.07.2006
GR20.07.2006
MC31.07.2006
PT19.09.2006
Former [2008/31]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
EE19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
BG19.07.2006
DK19.07.2006
SE19.07.2006
GR20.07.2006
MC31.07.2006
PT19.09.2006
Former [2008/28]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
EE19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
GR20.07.2006
MC31.07.2006
PT19.09.2006
Former [2008/21]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
GR20.07.2006
MC31.07.2006
PT19.09.2006
Former [2007/45]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
MC31.07.2006
PT19.09.2006
Former [2007/38]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
FI19.04.2006
IT19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
MC31.07.2006
PT19.09.2006
Former [2007/19]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
FI19.04.2006
LI19.04.2006
NL19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
MC31.07.2006
PT19.09.2006
Former [2007/13]AT19.04.2006
BE19.04.2006
CH19.04.2006
CZ19.04.2006
FI19.04.2006
LI19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
PT19.09.2006
Former [2007/11]AT19.04.2006
CH19.04.2006
CZ19.04.2006
FI19.04.2006
LI19.04.2006
SK19.04.2006
DK19.07.2006
SE19.07.2006
PT19.09.2006
Former [2007/03]AT19.04.2006
CH19.04.2006
FI19.04.2006
LI19.04.2006
SE19.07.2006
Former [2006/52]AT19.04.2006
FI19.04.2006
SE19.07.2006
Former [2006/48]SE19.07.2006
Cited inInternational search[X]WO9908501  (REDDY RESEARCH FOUNDATION [IN], et al) [X] 1-15 * page 4, line 11 - page 5, line 4; examples 27,28,32; claim 1 *;
 [X]WO0023425  (NOVO NORDISK AS [DK], et al) [X] 1-15 * page 1, line 5 - line 10; examples 1-6; claim 1 *;
 [X]WO0066572  (REDDY RESEARCH FOUNDATION [IN], et al) [X] 1-15 * page 8, line 10 - page 9, line 24; examples 2,5,6,32,33,43; claim 1 *;
 [X]EP1067109  (ONO PHARMACEUTICAL CO [JP]) [X] 1-15 * claim 1; tables 1-20 *;
 [X]WO0117994  (GLAXO GROUP LTD [GB], et al) [X] 1-15* page 6, line 28 - page 8, line 12; claim 1 *;
 [X]US6274608  (SAUERBERG PER [DK], et al) [X] 1-15 * column 1, line 15 - line 25; claim 1 *
Examination   - SHINKAI H. ET AL, "Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1998), vol. 41, no. 11, pages 1927 - 1933, XP002176728

DOI:   http://dx.doi.org/10.1021/jm970771m
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.